Search Results - "Loconsole, F."

Brodalumab for the treatment of moderate‐to‐severe plaque‐type psoriasis: a real‐life, retrospective 24‐week experience by Fargnoli, M.C., Esposito, M., Dapavo, P., Parodi, A., Rossi, M., Tiberio, R., Dastoli, S., Offidani, A.M., Argenziano, G., Gisondi, P., Lo Schiavo, A., Loconsole, F., Pella, P., Bardazzi, F., Cusano, F., Gattoni, M., Nacca, M., Cannavò, S.P., Pellegrini, C., Costanzo, A., Pertusi, G., Stroppiana, E., Gambardella, A., Romano, F., Sassetti, C., Carpentieri, A., Bellinato, F., Burlando, M., Graziola, F., Sacchelli, L., Campanati, A., Ronza, G.

“…Background Brodalumab was efficacious and safe in moderate‐to‐severe plaque‐type psoriasis in the AMAGINE trials; published reports under real‐life conditions…”
Get full text

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study by Esposito, M., Gisondi, P., Cassano, N., Ferrucci, G., Del Giglio, M., Loconsole, F., Giunta, A., Vena, G.A., Chimenti, S., Girolomoni, G.

“…Summary Background Adherence is an overall marker of treatment success, and it depends on multiple factors including efficacy and safety. Despite the wide use…”
Get full text

A risankizumab super responder profile identified by long‐term real‐life observation‐IL PSO (ITALIAN LANDSCAPE PSORIASIS) by Gargiulo, L., Ibba, L., Malagoli, P., Amoruso, F., Argenziano, G., Balato, A., Bardazzi, F., Burlando, M., Carrera, C. G., Damiani, G., Dapavo, P., Dini, V., Fabbrocini, G., Franchi, C., Gaiani, F. M., Girolomoni, G., Guarneri, C., Lasagni, C., Loconsole, F., Marzano, A. V., Maurelli, M., Megna, M., Orsini, D., Sampogna, F., Travaglini, M., Valenti, M., Costanzo, A., Narcisi, A.

Get full text

Long‐term effectiveness and tolerability of apremilast in patients with moderate‐to‐severe plaque psoriasis: A 5‐year multicentre retrospective study—IL PSO (Italian landscape psoriasis) by Gargiulo, L., Ibba, L., Malagoli, P., Amoruso, F., Balato, A., Bardazzi, F., Burlando, M., Carrera, C. G., Dapavo, P., Dini, V., Gaiani, F. M., Girolomoni, G., Guarneri, C., Lasagni, C., Loconsole, F., Marzano, A. V., Maurelli, M., Megna, M., Travaglini, M., Costanzo, A., Narcisi, A.

Get full text

A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in Italy by Capri, Stefano, Migliore, A, Loconsole, F, Barbieri, Marco

“…The aim of this study was to conduct a cost-effectiveness analysis, as well as a budget impact analysis, on the use of apremilast for the treatment of adult…”
Get more information

A cost-effectiveness and budget impact analysis of apremilast in patients with psoriasis in the Italian setting by Barbieri, Marco, Loconsole, F, Migliore, A, Capri, S

“…The aim of this study was to conduct a cost-effectiveness analysis, as well as a budget impact analysis, on the use of apremilast for the treatment of adult…”
Get more information

Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study by Bonifati, C, Lembo, S, Richetta, A G, Romanelli, M, Satolli, F, Corazza, M, Atzori, L, Lasagni, C, Potenza, C, Savoia, P, Bardazzi, F, Di Lernia, V G, Bianchi, L, Fabbrocini, G, Giofrè, C, Zichichi, L, Guarneri, C, Pallotta, S, Fargnoli, M C, Loconsole, F, Offidani, A, Burlando, M, Piaserico, S, Peris, K, Papini, M, Carrera, C G, Costanzo, A, Prignano, F, Bongiorno, R, Dapavo, P, Stingeni, L, Donini, M, Micali, G, Rongioletti, F, Stinco, G, Gramiccia, T, Cantini, G, Argenziano, G

“…Facial (FP) and genital psoriasis (GP) significantly affect patients' quality of life. Despite the advances in treatments, limited data on efficacy and safety…”
Get full text

Clusterin serum level: how does it affect psoriatic patients? by Buquicchio, R, Foti, C, Loconsole, F, Polimeno, L, Ventura, M T

“…Psoriasis is a chronic inflammatory skin disease with systemic involvement that might predispose to many psoriasis-related comorbidities, such as metabolic…”
Get more information

Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study by Stingeni, Luca, Malara, Giovanna, Conti, Andrea, Di Costanzo, Luisa, Carrera, Carlo Giovanni, Burlando, Martina, Malagoli, Piergiorgio, Musumeci, Maria Letizia, Bardazzi, Federico, Brazzelli, Valeria, Amerio, Paolo, De Simone, Clara, Trevisini, Sara, Balato, Anna, Megna, Matteo, Loconsole, Francesco, De Felice, Catia, Bartezaghi, Marta, Rausa, Alice, Aloisi, Elisabetta, Orsenigo, Roberto, Costanzo, Antonio

“…Psoriasis, a common systemic inflammatory disorder, presents with gender-related differences in the quality of life (QoL) and treatment outcomes. This post hoc…”
Get full text

Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease by Cassano, N, Mastrandrea, V, Principi, M, Loconsole, F, De Tullio, N, Di Leo, A, Vena, G A

“…One of the problems possibly related to the use of biological agents targeting tumor necrosis factor (TNF)-alpha is the increased risk of infections, including…”
Get more information

Investigating psoriasis awareness among patients in Italy: validation of a questionnaire by Bardazzi, F, Amerio, P, Amoruso, G, Campanati, A, Conti, A, De Simone, C, Gisondi, P, Gualdi, G, Guarneri, C, Loconsole, F, Mazzotta, A, Musumeci, M L, Odorici, G, Piaserico, S, Potenza, C, Scudeller, L

“…Psoriasis can have a profound impact on quality of life (QoL) and an awareness of the processes of the disease and its treatment is important in coping with…”
Get more information

Infliximab in recalcitrant severe atopic eczema associated with contact allergy by Cassano, N, Loconsole, F, Coviello, C, Vena, G A

“…Infliximab is an anti-tumour necrosis factor (TNF)-alpha chimeric monoclonal antibody which is effective in diseases associated with a T-helper (Th) 1…”
Get more information

Combination of Etanercept and Twice-Weekly Administration of Cyclosporin in Psoriasis Unsatisfactorily Controlled by Etanercept Monotherapy: A Retrospective Analysis by Vena, G.A., Mastrandrea, V., Battaglini, S., Loconsole, F., Buquicchio, R., Cassano, N.

“…Combination of systemic biological and traditional agents is increasingly used for the treatment of “high-need” patients with psoriasis. There are only limited…”
Get full text

Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study Group by Cassano, N, Loconsole, F, Miracapillo, A, Travaglini, M, Digiuseppe, M D, Congedo, M, Galluccio, A, Buquicchio, R, Mastrandrea, V, Filieri, M, Raho, G, Pezza, M, Vena, G A

“…This pilot open-label study is aimed to assess clinical response in psoriasis patients receiving diverse dose regimens of etanercept, consisting of the same…”
Get more information

Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data by Cassano, N, Galluccio, A, De Simone, C, Loconsole, F, Massimino, S D, Plumari, A, Dattola, S, Puglisi Guerra, A, Donato, L, Cantoresi, F, De Pita, O, Fenizi, G, Altamura, V, Congedo, M, Pellicano, R, Vena, G A

“…Adalimumab is a fully human monoclonal antibody directed against tumor necrosis factor (TNF)-alpha, which is effective for the treatment of psoriasis and…”
Get full text

Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study) by Cassano, N, Loconsole, F, Galluccio, A, Miracapillo, A, Pezza, M, Vena, G A

“…Etanercept is a soluble tumour necrosis factor receptor fusion protein which is approved for the treatment of plaque psoriasis at the dose of either 25mg twice…”
Get more information

Is there an association between antiphospholipid antibodies and psoriasis? by Cassano, N, Buquicchio, R, Ranieri, V, Loconsole, F, Vena, G A

“…Ever increasing evidence supports the association between psoriasis and cardiovascular risk. Antiphospholipid antibodies (APAs), which can occur in many…”
Get full text

Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriatic patients by Cassano, N, Puglisi Guerra, A, Malara, C, Loconsole, F, Galluccio, A, Pezza, M, Vena, G A

“…Infliximab is an anti-tumour necrosis factor-alpha chimeric monoclonal antibody which is highly effective in psoriasis, as well as in other indications. In…”
Get more information

Efalizumab in moderate-to-severe plaque psoriasis: a retrospective case series analysis from clinical practice by Cassano, N, Mastrandrea, V, Buquicchio, R, Miracapillo, A, Loconsole, F, Filotico, R, Vena, G A

“…Efalizumab is an anti-CD11a humanized monoclonal antibody which is safe and effective for the treatment of plaque psoriasis. We performed a retrospective…”
Get full text

Infliximab monotherapy for refractory psoriasis: preliminary results by Cassano, N, Loconsole, F, Amoruso, A, Coviello, C, Filieri, M, Filotico, R, Del Vecchio, S, Vena, G A

“…Tumour necrosis factor (TNF)-alpha plays an important role in the pathogenesis of psoriasis. Infliximab is an anti-TNF-alpha chimeric monoclonal antibody,…”
Get more information